|
Market Closed -
Nasdaq
01:30:00 17/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 62.23 USD | -0.95% |
|
+3.96% | +41.98% |
| 09/10 | Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says | MT |
| 09/10 | RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.54TCr | |||||
| 6.5TCr | |||||
| 5.12TCr | |||||
| 5.12TCr | |||||
| 4.39TCr | |||||
| 4.2TCr |
- Stock Market
- Stocks
- EXEL Stock
- Charts Exelixis, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
